Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF 66.5 million on May 4, 2021. Under the term sheet, Relief Therapeutics Holding AG shall pay CHF 21.5 million in cash along with CHF 45 million through the issuance of shares. Relief Therapeutics Holding AG shall also pay contingent payments in the form of cash and shares upon achievement of pre-agreed contingent milestones. In addition, as part of the transaction, an individual to-be-named will stand for election as APR Applied Pharma Research s.a.'s designee at Relief’s Annual General Meeting of Shareholders scheduled for June 18, 2021. For a period of 60 days, Relief has the exclusive right to negotiate and close the transaction on the basis of the terms and conditions in the signed term sheet. The acquisition of APR Applied Pharma Research s.a. is expected to be immediately accretive to Relief Therapeutics Holding AG 's earnings. Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a. on June 29, 2021.